# Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

> **NCT04967196** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 6 (actual)

## Conditions studied

- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Melanoma
- Unresectable Melanoma

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab
- **PROCEDURE:** Lymph Node Assessment
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT04967196
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-16
- **Primary completion:** 2024-04-17
- **Final completion:** 2024-04-17
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04967196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04967196, "Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04967196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*